Fazio, Sergio

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 3,962

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 1,601

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 984

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 743

The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk

Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 608

PCSK9: From Basic Science Discoveries to Clinical Trials

Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 285

The Evolving Future of PCSK9 Inhibitors

Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 264

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary

Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 248

From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk

Shapiro, M. D., & Fazio, S. (2016) · Circulation Research

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 217

Macrophage LRP-1 Controls Plaque Cellularity by Regulating Efferocytosis and Akt Activation

Yancey, P. G., Blakemore, J., Ding, L., Fan, D., Overton, C. D., Zhang, Y., Linton, M. F., & Fazio, S. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology

Phagocytosis and Immune RegulationAtherosclerosis and Cardiovascular Diseases

Cited by 168

Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis

Tao, H., Yancey, P. G., Babaev, V. R., Blakemore, J. L., Zhang, Y., Ding, L., Fazio, S., & Linton, M. F. (2015) · Journal of Lipid Research

Phagocytosis and Immune RegulationAtherosclerosis and Cardiovascular Diseases

Cited by 143

Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.

Ji, Z. S., Fazio, S., & Mahley, R. W. (1994) · Journal of Biological Chemistry

Cholesterol and Lipid MetabolismLipid metabolism and disorders

Cited by 138

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol

Nichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2019) · Diabetes, Obesity and Metabolism

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 125

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size

Tsimikas, S., Fazio, S., Viney, N. J., Xia, S., Witztum, J. L., & Marcovina, S. M. (2018) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 109

A systematic review of PCSK9 inhibitors alirocumab and evolocumab

McDonagh, M., Peterson, K., Holzhammer, B., & Fazio, S. (2016) · Journal of Managed Care & Specialty Pharmacy

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 103

Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol

Nichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2018) · The Journal of Clinical Endocrinology & Metabolism

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 102

Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study

Bartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 96

On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects

Tavori, H., Rashid, S., & Fazio, S. (2015) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 86

Low-Density Lipoprotein Receptor–Related Protein 1 Prevents Early Atherosclerosis by Limiting Lesional Apoptosis and Inflammatory Ly-6C high Monocytosis: Evidence That the Effects Are Not Apolipoprotein E Dependent

Yancey, P. G., Ding, Y., Fan, D., Blakemore, J. L., Zhang, Y., Ding, L., Zhang, J., Linton, M. F., & Fazio, S. (2011) · Circulation

Atherosclerosis and Cardiovascular DiseasesCholesterol and Lipid Metabolism

Cited by 83

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Shapiro, M. D., Minnier, J., Tavori, H., Kassahun, H., Flower, A., Somaratne, R., & Fazio, S. (2019) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 70

Real-world utilization of bempedoic acid in an academic preventive cardiology practice

Warden, B. A., Cardiology, B.-A., Purnell, J. Q., Duell, P. B., & Fazio, S. (2022) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 39

Chylomicronemia syndrome: Familial or not?

Warden, B. A., Minnier, J., Duell, P. B., Fazio, S., & Shapiro, M. D. (2020) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 34

PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9

Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 30

Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.

Fazio, S., Horie, Y., Weisgraber, K., Havekes, L., & Rall, S. (1993) · Journal of Lipid Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 23